カルメット菌（BCG）ワクチンの世界市場

カルメット菌（BCG）ワクチンの世界市場は2030年までに1億1,330万米ドルに達する見込み

2024年に9,040万米ドルと推定されるカルメット菌（BCG）ワクチンの世界市場は、2024年から2030年にかけてCAGR 3.8%で成長し、2030年には1億1,330万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである小児科は、CAGR 4.8%を記録し、分析期間終了時には6,030万米ドルに達すると予測されます。成人セグメントの成長率は、分析期間中CAGR 2.8%と推定されます。

米国市場は2,460万米ドルと推定、中国はCAGR 7.3％で成長すると予測

米国のカルメット菌（BCG）ワクチン市場は、2024年に2,460万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに2,310万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.5％と3.0％と予測されています。欧州では、ドイツがCAGR 2.2%で成長すると予測されています。

世界のカルメット菌（BCG）ワクチン市場- 主要動向と促進要因まとめ

なぜBCGワクチンは依然として結核対策に不可欠なのか？

BCGワクチンは、結核との世界の闘いにおいて最も重要なツールの1つであり、特に中低所得国において公衆衛生上の大きな課題をもたらし続けています。約1世紀前に初めて導入されたBCGワクチンは、特に小児の髄膜炎や粟粒結核などの重症結核の予防に高い効果があることが証明されています。BCGワクチンは、結核の蔓延率が高い国々における国家予防接種プログラムの要であり、小児期の罹患率と死亡率を減少させる上で極めて重要な役割を果たしています。さらに、このワクチンの非結核性抗酸菌感染症に対する予防効果や、膀胱がんなどある種のがんを予防する効果が期待されることから、その重要性はさらに高まっています。結核撲滅に向けた世界の取り組みが強化される中、世界保健機関（WHO）をはじめとする保健機関は、健康の公平性を達成し、感染症をコントロールするための広範な戦略の一環として、BCGワクチンの配布を優先しています。古いワクチンであるにもかかわらず、BCGの関連性が継続していることは、世界保健におけるBCGの不可欠な役割を強調しています。

生産と流通の進歩はワクチンへのアクセスをどのように向上させているか？

BCGワクチン市場は、生産と流通のインフラストラクチャーにおいて大きな進歩を遂げており、必要とする人々へのアクセスを確保しています。製造業者はワクチンの安定性、保存性、拡張性を高めるため、最新の製造技術に投資してきました。例えば、ワクチンの凍結乾燥製剤は、特にコールドチェーン機能が限られている地域での輸送や保管をより便利にしています。また、高度なバイオ製造技術の利用により、製造者は生産量を拡大することが可能となり、各国の予防接種プログラムによる需要の高まりに応えることができるようになりました。さらに、Gavi、Vaccine Alliance、UNICEFなどの世界・ヘルス・イニシアチブは、特に資源に制約のある環境において、ワクチンの調達と流通を改善する上で重要な役割を果たしています。政府、非政府組織、製薬企業間の協力的パートナーシップにより、遠隔地や十分なサービスを受けていない地域であっても、ワクチンの効率的な供給が確保されています。このような進歩は、ワクチン衡平性のギャップを埋め、BCGの恩恵が世界中の脆弱な人々に届くことを確実にするのに役立っています。

BCGワクチン普及の地域差はどのような要因によってもたらされているのか？

BCGワクチンの普及は地域によって大きく異なり、地域の結核流行状況、ヘルスケアインフラ、政策の優先順位に影響されます。アフリカ、南アジア、東南アジアの一部など、結核罹患率の高い地域では、BCGワクチン接種が国の予防接種スケジュールの一部として義務付けられています。これらの地域は人口密度が高く、結核の感染率が比較的高いため、世界のワクチン需要の大きな割合を占めています。逆に、米国や西欧の大部分など、結核の感染率が低い国々では、BCGワクチンの接種は通常、医療従事者や流行地域への旅行者など、特定の高リスクグループに限られています。また、薬剤耐性結核株に対する懸念が高まっている地域では、より的を絞った介入策が開発されるまでの間、予防的な役割を果たすワクチンとして、再び注目を集めています。このような地域差は、公衆衛生政策、啓発キャンペーン、予防接種プログラムに対する資金の有無によっても形成されます。こうしたダイナミクスを理解することは、生産・流通戦略を地域のニーズに合致させる上で極めて重要です。

BCGワクチン市場の成長を促す要因とは？

BCGワクチン市場の成長は、結核の持続的な流行、ワクチン製造の進歩、予防接種範囲の拡大など、いくつかの要因によって牽引されています。結核の罹患率が高い地域では、国の結核対策プログラムにおける第一線の防御手段であるBCGワクチンの需要が引き続き高まっています。凍結乾燥製剤やコールドチェーンロジスティクスの改善など、ワクチン製造における技術革新は、予防接種キャンペーンの拡張性と到達度を高めています。また、WHOやGaviのような組織からの資金援助による世界・ヘルス・イニシアチブも、中低所得国における予防接種率の拡大に重要な役割を果たしています。さらに、膀胱がんなどの非結核性疾患の予防におけるワクチンの役割は、腫瘍学での採用の機会を生み出しています。薬剤耐性結核菌に対する意識の高まりは、予防対策の重要性をさらに浮き彫りにし、BCGワクチンの需要を世界的に押し上げています。最後に、ワクチンの有効性を最適化し、免疫療法への応用の可能性を探る継続的な調査により、市場成長の新たな道が開かれつつあり、この歴史的かつ重要なワクチンの継続的な関連性が確保されつつあります。

セグメント

年齢層（小児科、成人）、用途（結核用途、膀胱がん用途）、最終用途（病院最終用途、診療所最終用途）

調査対象企業の例

• AJ Vaccines
• BB-NCIPD Ltd.（Bul Bio）
• BioFarma
• Biological E. Limited
• Bio-Manguinhos/Fiocruz
• Biomed-Lublin Wytwornia Surowic i Szczepionek SA
• China National Pharmaceutical Group（Sinopharm）
• GreenSignal Bio Pharma Pvt. Ltd.
• Haffkine Bio-Pharmaceutical Corporation Ltd.
• InterVax Ltd.
• Japan BCG Laboratory
• Merck & Co., Inc.
• Microgen
• Sanofi Pasteur
• Serbia Torlak Institute
• Serum Institute of India Pvt. Ltd.
• Serum Institute of India Pvt. Ltd.
• Shantha Biotechnics Pvt. Ltd.
• Statens Serum Institut
• Vacsera

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Bacillus Calmette-Guerin (BCG) Vaccines Market to Reach US$113.3 Million by 2030

The global market for Bacillus Calmette-Guerin (BCG) Vaccines estimated at US$90.4 Million in the year 2024, is expected to reach US$113.3 Million by 2030, growing at a CAGR of 3.8% over the analysis period 2024-2030. Pediatrics, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$60.3 Million by the end of the analysis period. Growth in the Adults segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$24.6 Million While China is Forecast to Grow at 7.3% CAGR

The Bacillus Calmette-Guerin (BCG) Vaccines market in the U.S. is estimated at US$24.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$23.1 Million by the year 2030 trailing a CAGR of 7.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 3.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Bacillus Calmette-Guerin (BCG) Vaccines Market - Key Trends & Drivers Summarized

Why Are BCG Vaccines Still Crucial in Combating Tuberculosis?

BCG vaccines remain one of the most important tools in the global fight against tuberculosis (TB), a disease that continues to pose a major public health challenge, particularly in low- and middle-income countries. First introduced nearly a century ago, the BCG vaccine has proven to be highly effective in preventing severe forms of TB, including meningitis and miliary TB, particularly in children. The vaccine is a cornerstone of national immunization programs in countries with high TB prevalence, where it plays a pivotal role in reducing childhood morbidity and mortality. Moreover, the vaccine’s protective effects against non-tuberculous mycobacterial infections and its potential benefits in preventing certain types of cancer, such as bladder cancer, have further solidified its importance. As global efforts to eliminate TB intensify, the World Health Organization (WHO) and other health organizations are prioritizing BCG vaccine distribution as part of their broader strategies to achieve health equity and control infectious diseases. Despite being an older vaccine, the continued relevance of BCG underscores its indispensable role in global health.

How Are Advancements in Production and Distribution Enhancing Vaccine Accessibility?

The BCG vaccine market has witnessed significant advancements in production and distribution infrastructure, ensuring that it remains accessible to populations in need. Manufacturers have been investing in modernized production techniques to enhance vaccine stability, shelf life, and scalability. For example, lyophilized (freeze-dried) formulations of the vaccine have made transportation and storage more convenient, especially in regions with limited cold-chain capabilities. The use of advanced biomanufacturing technologies has also enabled producers to scale up output, meeting the growing demand from national immunization programs. Additionally, global health initiatives, such as Gavi, the Vaccine Alliance, and UNICEF, have played a crucial role in improving vaccine procurement and distribution, particularly in resource-constrained settings. Collaborative partnerships between governments, non-governmental organizations, and pharmaceutical companies are ensuring that vaccines are delivered efficiently, even to remote or underserved areas. These advancements are helping to bridge the gap in vaccine equity, ensuring that the benefits of BCG reach vulnerable populations worldwide.

Which Factors Are Driving Regional Variations in BCG Vaccine Adoption?

The adoption of BCG vaccines varies widely across regions, influenced by local TB prevalence, healthcare infrastructure, and policy priorities. In high-burden regions such as Africa, South Asia, and parts of Southeast Asia, BCG vaccination is a mandatory part of national immunization schedules, reflecting the critical need to combat TB. These regions account for a significant share of the global vaccine demand due to their high population densities and relatively higher rates of TB transmission. Conversely, in low-burden countries such as the United States and much of Western Europe, BCG vaccination is typically reserved for specific high-risk groups, such as healthcare workers or individuals traveling to endemic areas. The vaccine is also gaining renewed attention in regions with growing concerns about drug-resistant TB strains, as it provides a preventive layer while more targeted interventions are developed. Regional variations in adoption are further shaped by public health policies, awareness campaigns, and the availability of funding for immunization programs. Understanding these dynamics is critical for aligning production and distribution strategies with local needs.

What Factors Are Propelling Growth in the BCG Vaccines Market?

The growth in the BCG vaccines market is driven by several factors, including the persistent prevalence of tuberculosis, advancements in vaccine manufacturing, and expanded immunization coverage. High TB burden regions continue to drive demand for BCG vaccines, as they form the first line of defense in national TB control programs. Innovations in vaccine production, such as lyophilized formulations and improved cold-chain logistics, have enhanced the scalability and reach of vaccination campaigns. Global health initiatives, supported by funding from organizations like WHO and Gavi, have also played a crucial role in expanding immunization coverage in low- and middle-income countries. Additionally, the vaccine’s role in preventing non-tuberculous diseases, such as bladder cancer, has created opportunities for its adoption in oncology. Rising awareness about drug-resistant TB strains has further highlighted the importance of preventive measures, boosting demand for BCG vaccines globally. Lastly, ongoing research into optimizing vaccine efficacy and exploring its potential in immunotherapy applications is creating new avenues for market growth, ensuring the continued relevance of this historic yet vital vaccine.

SCOPE OF STUDY:

The report analyzes the Bacillus Calmette-Guerin (BCG) Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Age Group (Pediatrics, Adults); Application (Tuberculosis Application, Bladder Cancer Application);End-Use (Hospitals End-Use, Clinics End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• AJ Vaccines
• BB-NCIPD Ltd. (Bul Bio)
• BioFarma
• Biological E. Limited
• Bio-Manguinhos/Fiocruz
• Biomed-Lublin Wytwornia Surowic i Szczepionek SA
• China National Pharmaceutical Group (Sinopharm)
• GreenSignal Bio Pharma Pvt. Ltd.
• Haffkine Bio-Pharmaceutical Corporation Ltd.
• InterVax Ltd.
• Japan BCG Laboratory
• Merck & Co., Inc.
• Microgen
• Sanofi Pasteur
• Serbia Torlak Institute
• Serum Institute of India Pvt. Ltd.
• Serum Institute of India Pvt. Ltd.
• Shantha Biotechnics Pvt. Ltd.
• Statens Serum Institut
• Vacsera

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Bacillus Calmette-Guerin (BCG) Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Global TB Control Initiatives Propel Sustained Demand for BCG Vaccine Administration
  • Government Immunization Programs Strengthen Business Case for BCG Vaccine Supply Contracts
  • World Health Organization (WHO) Recommendations Drive Global Standardization of BCG Vaccination
  • Cold Chain Logistics and Vaccine Storage Infrastructure Challenges Impact BCG Distribution Efficiency
  • Public Health Campaigns and Awareness Programs Generate Demand for Infant BCG Vaccination
  • Vaccine Manufacturing Capacity Expansion Sustains Supply Stability and Market Growth
  • Innovation in Needle-Free and Oral Vaccine Delivery Methods Throws Spotlight on Next-Gen BCG Options
  • Global Health Funding and Donor Support Propel Vaccination Coverage and Accessibility
  • Safety, Efficacy, and Adverse Reaction Monitoring Drive Demand for Pharmacovigilance in BCG Deployment
  • Epidemiological Data and TB Surveillance Systems Generate Demand for Targeted BCG Campaigns
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Bacillus Calmette-Guerin (BCG) Vaccines Market Analysis of Annual Sales in US$ for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Pediatrics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Pediatrics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Pediatrics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Adults by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Adults by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Adults by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Tuberculosis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Tuberculosis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Tuberculosis Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Bladder Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Bladder Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Bladder Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Bacillus Calmette-Guerin (BCG) Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 23: USA Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 24: USA Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 25: USA 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • TABLE 26: USA Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 28: USA 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Percentage Breakdown of Value Sales for Tuberculosis Application and Bladder Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 29: USA Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 31: USA 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 34: Canada 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 37: Canada 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Percentage Breakdown of Value Sales for Tuberculosis Application and Bladder Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 40: Canada 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2015, 2025 & 2030
• JAPAN
  • Bacillus Calmette-Guerin (BCG) Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 41: Japan Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Japan Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 43: Japan 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • TABLE 44: Japan Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Japan Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 46: Japan 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Percentage Breakdown of Value Sales for Tuberculosis Application and Bladder Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 49: Japan 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2015, 2025 & 2030
• CHINA
  • Bacillus Calmette-Guerin (BCG) Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 50: China Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 51: China Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 52: China 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • TABLE 53: China Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 54: China Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 55: China 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Percentage Breakdown of Value Sales for Tuberculosis Application and Bladder Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 56: China Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 58: China 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2015, 2025 & 2030
• EUROPE
  • Bacillus Calmette-Guerin (BCG) Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 59: Europe Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 60: Europe Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 61: Europe 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 62: Europe Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Europe Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 64: Europe 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 67: Europe 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Percentage Breakdown of Value Sales for Tuberculosis Application and Bladder Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2015, 2025 & 2030
• FRANCE
  • Bacillus Calmette-Guerin (BCG) Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 71: France Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 72: France Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 73: France 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • TABLE 74: France Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 75: France Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 76: France 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Percentage Breakdown of Value Sales for Tuberculosis Application and Bladder Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 77: France Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 78: France Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 79: France 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2015, 2025 & 2030
• GERMANY
  • Bacillus Calmette-Guerin (BCG) Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 80: Germany Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Germany Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 82: Germany 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • TABLE 83: Germany Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Germany Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 85: Germany 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Percentage Breakdown of Value Sales for Tuberculosis Application and Bladder Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 86: Germany Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Germany Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 88: Germany 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 89: Italy Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Italy Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 91: Italy 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • TABLE 92: Italy Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Italy Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 94: Italy 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Percentage Breakdown of Value Sales for Tuberculosis Application and Bladder Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 95: Italy Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Italy Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 97: Italy 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Bacillus Calmette-Guerin (BCG) Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 98: UK Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 99: UK Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 100: UK 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • TABLE 101: UK Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 102: UK Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 103: UK 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Percentage Breakdown of Value Sales for Tuberculosis Application and Bladder Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 104: UK Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 105: UK Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 106: UK 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 107: Spain Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Spain Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 109: Spain 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • TABLE 110: Spain Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Spain Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 112: Spain 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Percentage Breakdown of Value Sales for Tuberculosis Application and Bladder Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 113: Spain Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Spain Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 115: Spain 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 116: Russia Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Russia Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 118: Russia 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • TABLE 119: Russia Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Russia Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 121: Russia 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Percentage Breakdown of Value Sales for Tuberculosis Application and Bladder Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 122: Russia Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Russia Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 124: Russia 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Rest of Europe Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 127: Rest of Europe 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Rest of Europe Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 130: Rest of Europe 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Percentage Breakdown of Value Sales for Tuberculosis Application and Bladder Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Rest of Europe Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 133: Rest of Europe 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Bacillus Calmette-Guerin (BCG) Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 135: Asia-Pacific Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 136: Asia-Pacific 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Asia-Pacific Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 139: Asia-Pacific 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Asia-Pacific Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 142: Asia-Pacific 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Percentage Breakdown of Value Sales for Tuberculosis Application and Bladder Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Bacillus Calmette-Guerin (BCG) Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 146: Australia Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Australia Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 148: Australia 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • TABLE 149: Australia Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Australia Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 151: Australia 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Percentage Breakdown of Value Sales for Tuberculosis Application and Bladder Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 152: Australia Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Australia Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 154: Australia 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2015, 2025 & 2030
• INDIA
  • Bacillus Calmette-Guerin (BCG) Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 155: India Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 156: India Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 157: India 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • TABLE 158: India Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 159: India Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 160: India 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Percentage Breakdown of Value Sales for Tuberculosis Application and Bladder Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 161: India Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 162: India Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 163: India 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 164: South Korea Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 165: South Korea Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 166: South Korea 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • TABLE 167: South Korea Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 168: South Korea Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 169: South Korea 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Percentage Breakdown of Value Sales for Tuberculosis Application and Bladder Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 170: South Korea Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 171: South Korea Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 172: South Korea 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 173: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Rest of Asia-Pacific Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 175: Rest of Asia-Pacific 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • TABLE 176: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Rest of Asia-Pacific Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 178: Rest of Asia-Pacific 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Percentage Breakdown of Value Sales for Tuberculosis Application and Bladder Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Asia-Pacific Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Bacillus Calmette-Guerin (BCG) Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 182: Latin America Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 183: Latin America Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 184: Latin America 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 185: Latin America Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Latin America Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 187: Latin America 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • TABLE 188: Latin America Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Latin America Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 190: Latin America 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Percentage Breakdown of Value Sales for Tuberculosis Application and Bladder Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 193: Latin America 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 194: Argentina Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Argentina Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 196: Argentina 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • TABLE 197: Argentina Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Argentina Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 199: Argentina 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Percentage Breakdown of Value Sales for Tuberculosis Application and Bladder Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 200: Argentina Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Argentina Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 202: Argentina 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 203: Brazil Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Brazil Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 205: Brazil 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • TABLE 206: Brazil Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Brazil Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 208: Brazil 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Percentage Breakdown of Value Sales for Tuberculosis Application and Bladder Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 209: Brazil Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Brazil Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 211: Brazil 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 212: Mexico Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Mexico Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 214: Mexico 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • TABLE 215: Mexico Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Mexico Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 217: Mexico 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Percentage Breakdown of Value Sales for Tuberculosis Application and Bladder Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 218: Mexico Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Mexico Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 220: Mexico 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 221: Rest of Latin America Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Rest of Latin America Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 223: Rest of Latin America 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • TABLE 224: Rest of Latin America Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Rest of Latin America Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 226: Rest of Latin America 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Percentage Breakdown of Value Sales for Tuberculosis Application and Bladder Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Rest of Latin America Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 229: Rest of Latin America 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Bacillus Calmette-Guerin (BCG) Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 230: Middle East Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 231: Middle East Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 232: Middle East 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 233: Middle East Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Middle East Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 235: Middle East 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • TABLE 236: Middle East Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Middle East Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 238: Middle East 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Percentage Breakdown of Value Sales for Tuberculosis Application and Bladder Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 241: Middle East 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 242: Iran Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Iran Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 244: Iran 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • TABLE 245: Iran Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Iran Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 247: Iran 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Percentage Breakdown of Value Sales for Tuberculosis Application and Bladder Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 248: Iran Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Iran Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 250: Iran 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 251: Israel Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Israel Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 253: Israel 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • TABLE 254: Israel Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Israel Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 256: Israel 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Percentage Breakdown of Value Sales for Tuberculosis Application and Bladder Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 257: Israel Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Israel Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 259: Israel 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 260: Saudi Arabia Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Saudi Arabia Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 262: Saudi Arabia 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • TABLE 263: Saudi Arabia Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Saudi Arabia Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 265: Saudi Arabia 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Percentage Breakdown of Value Sales for Tuberculosis Application and Bladder Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Saudi Arabia Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 268: Saudi Arabia 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 269: UAE Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 270: UAE Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 271: UAE 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • TABLE 272: UAE Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 273: UAE Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 274: UAE 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Percentage Breakdown of Value Sales for Tuberculosis Application and Bladder Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 275: UAE Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 276: UAE Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 277: UAE 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 278: Rest of Middle East Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Rest of Middle East Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 280: Rest of Middle East 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • TABLE 281: Rest of Middle East Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Rest of Middle East Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 283: Rest of Middle East 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Percentage Breakdown of Value Sales for Tuberculosis Application and Bladder Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Rest of Middle East Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 286: Rest of Middle East 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2015, 2025 & 2030
• AFRICA
  • Bacillus Calmette-Guerin (BCG) Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 287: Africa Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Africa Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 289: Africa 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2015, 2025 & 2030
  • TABLE 290: Africa Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Africa Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Tuberculosis Application and Bladder Cancer Application Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 292: Africa 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by Application - Percentage Breakdown of Value Sales for Tuberculosis Application and Bladder Cancer Application for the Years 2015, 2025 & 2030
  • TABLE 293: Africa Recent Past, Current & Future Analysis for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Africa Historic Review for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Hospitals End-Use and Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 295: Africa 15-Year Perspective for Bacillus Calmette-Guerin (BCG) Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use and Clinics End-Use for the Years 2015, 2025 & 2030

IV. COMPETITION